HYDROCORTISONE BUTYRATE

Post-LOE

hydrocortisone butyrate

Teva

ANDATOPICALCREAM

Approved

Dec 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

HYDROCORTISONE BUTYRATE (hydrocortisone butyrate) by Teva is clinical pharmacology topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. Approved for atopic dermatitis. First approved in 2017.

Drug data last refreshed 23h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…

Indications (1)

atopic dermatitis

Worked on HYDROCORTISONE BUTYRATE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.